Analyst Ratings For Arca Biopharma (NASDAQ:ABIO)
Today, Ascendiant Capital Markets initiated coverage on Arca Biopharma (NASDAQ:ABIO) with a Buy with a price target of $2.00.
Some recent analyst ratings include
- 2/27/2018-Ascendiant Capital Markets initiated coverage with a Buy rating.
Recent Insider Trading Activity For Arca Biopharma (NASDAQ:ABIO)
Arca Biopharma (NASDAQ:ABIO) has insider ownership of 3.75% and institutional ownership of 37.33%.
- On 7/14/2017 Robert E Conway, Chairman, bought 10,000 with an average share price of $2.49 per share and the total transaction amounting to $24,900.00.
- On 5/2/2017 Daniel J Mitchell, Director, bought 11,000 with an average share price of $2.71 per share and the total transaction amounting to $29,810.00.
- On 4/4/2017 Christopher David Ozeroff, VP, sold 418 with an average share price of $2.41 per share and the total transaction amounting to $1,007.38.
- On 4/4/2017 Michael R. Bristow, Insider, sold 720 with an average share price of $2.41 per share and the total transaction amounting to $1,735.20.
- On 4/4/2017 Thomas A. Keuer, COO, sold 390 with an average share price of $2.41 per share and the total transaction amounting to $939.90.
- On 4/3/2017 Brian L. Selby, VP, sold 1,114 with an average share price of $2.46 per share and the total transaction amounting to $2,740.44.
- On 3/24/2017 Robert E Conway, Director, bought 25,000 with an average share price of $2.59 per share and the total transaction amounting to $64,750.00.
Recent Trading Activity for Arca Biopharma (NASDAQ:ABIO)
Shares of Arca Biopharma closed the previous trading session at 0.59 up +0.14 32.16% with 0.5 shares trading hands.